Top-line results are expected in approximately eight weeks.

Alphyn Biologics completed the first cohort of its Phase2a clinical trial of AB-101a, a topical therapeutic candidate for mild-to-moderate atopic dermatitis (AD) in adults and children as young as two years old. 

The first cohort enrolled AD patients without bacterial infection, which is sometimes associated with the disease. 

Top-line results are expected in approximately eight weeks.

AB-101a was developed using Alphyn's proprietary AB-101 platform. The platform has multiple bioactive compounds and, therefore, multiple mechanisms of action to potentially address multiple problems of any target disease. Alphyn began its clinical trial program in Phase 2 due to the strong safety profile of its AB-101 platform.

The randomized, vehicle-controlled, double-blind trial is evaluating the treatment protocol of AB-101a across multiple sites using standard scales for assessing AD. Enrollment is ongoing in a second cohort of the trial, which uniquely is investigating the treatment in AD patients who are also suffering from bacterial infections, including staphylococcus aureus, or Staph, and MRSA, the antibiotic-resistant Staph. Alphyn anticipates AB-101a will be effective against non-infected AD and infected AD and expects it will offer patients and physicians a comprehensive, safe, and convenient treatment option.